UK researcher discovers drug that shows promise in treating rare cancer
A recent study published in Thyroid journal found paclitaxel to have significant clinical activity against ATC, with 53% of patients showing improved survival time. The drug was infused continuously over 96 hours every three weeks for one to six treatments.